Can microfluidics address biomanufacturing challenges in drug/gene/cell therapies? | Zendy

Hon Fai Chan | Zendy; Siying Ma | Zendy; Kam W. Leong | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Can microfluidics address biomanufacturing challenges in drug/gene/cell therapies?

Author(s) -

Hon Fai Chan,

Siying Ma,

Kam W. Leong

Publication year - 2016

Publication title -

regenerative biomaterials

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.166

H-Index - 25

ISSN - 2056-3426

DOI - 10.1093/rb/rbw009

Subject(s) - biomanufacturing , microfluidics , nanotechnology , drug delivery , computer science , risk analysis (engineering) , microbiology and biotechnology , medicine , materials science , biology

Translation of any inventions into products requires manufacturing. Development of drug/gene/cell delivery systems will eventually face manufacturing challenges, which require the establishment of standardized processes to produce biologically-relevant products of high quality without incurring prohibitive cost. Microfluidicu technologies present many advantages to improve the quality of drug/gene/cell delivery systems. They also offer the benefits of automation. What remains unclear is whether they can meet the scale-up requirement. In this perspective, we discuss the advantages of microfluidic-assisted synthesis of nanoscale drug/gene delivery systems, formation of microscale drug/cell-encapsulated particles, generation of genetically engineered cells and fabrication of macroscale drug/cell-loaded micro-/nano-fibers. We also highlight the scale-up challenges one would face in adopting microfluidic technologies for the manufacturing of these therapeutic delivery systems.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research